InsiderTrades.com logo
Carl Dambkowski net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Carl Dambkowski Biography and Net Worth

Director of Oruka Therapeutics

Dr Dambkowski is Chief Medical Officer for Apogee Therapeutics.

He has spent the last 10 years as a strategic and clinical leader advising biotech and pharma companies on a range of research and development activities. Prior to joining Apogee, he was part of the core teams at QED Therapeutics and Origin Biosciences as they brought TRUSELTIQ (infigratinib) and NULIBRY (fosdenopterin) through regulatory review and FDA approval. Additionally, he has served as Associate at McKinsey & Company and co-founded the private medical device company Novonate, Inc.

Dr Dambkowski holds a BS and MD from Stanford University in addition to an MA from Columbia University.

What is Carl Dambkowski's net worth?

The estimated net worth of Carl Dambkowski is at least $4.09 million as of May 21st, 2026. Dambkowski owns 73,743 shares of Oruka Therapeutics stock worth more than $4,088,312 as of June 2nd. This net worth approximation does not reflect any other assets that Dambkowski may own. Learn More about Carl Dambkowski's net worth.

How do I contact Carl Dambkowski?

The corporate mailing address for Dambkowski and other Oruka Therapeutics executives is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. Oruka Therapeutics can also be reached via phone at 720-940-2100 and via email at [email protected]. Learn More on Carl Dambkowski's contact information.

Has Carl Dambkowski been buying or selling shares of Oruka Therapeutics?

Over the course of the past ninety days, Carl Dambkowski has sold $6,191,850.00 of Oruka Therapeutics stock. Most recently, Carl Dambkowski sold 105,000 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a transaction totalling $6,191,850.00. Following the completion of the sale, the director now directly owns 73,743 shares of the company's stock, valued at $4,348,624.71. Learn More on Carl Dambkowski's trading history.

Who are Oruka Therapeutics' active insiders?

Oruka Therapeutics' insider roster includes Arjun Agarwal (SVP), Carl Dambkowski (Director), Joana Goncalves (Chief Medical Officer), and Lawrence Klein (CEO). Learn More on Oruka Therapeutics' active insiders.

Are insiders buying or selling shares of Oruka Therapeutics?

In the last year, insiders at the sold shares 10 times. They sold a total of 160,055 shares worth more than $8,759,314.81. The most recent insider tranaction occured on May, 21st when Director Carl Dambkowski sold 105,000 shares worth more than $6,191,850.00. Insiders at Oruka Therapeutics own 23.5% of the company. Learn More about insider trades at Oruka Therapeutics.

Information on this page was last updated on 5/21/2026.

Carl Dambkowski Insider Trading History at Oruka Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2026Sell105,000$58.97$6,191,850.0073,743View SEC Filing Icon  
See Full Table

Carl Dambkowski Buying and Selling Activity at Oruka Therapeutics

This chart shows Carl Dambkowski's buying and selling at Oruka Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oruka Therapeutics Company Overview

Oruka Therapeutics logo
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $55.06
Low: $53.62
High: $57.86

50 Day Range

MA: $60.02
Low: $38.91
High: $76.39

2 Week Range

Now: $55.06
Low: $10.77
High: $91.00

Volume

1,123,196 shs

Average Volume

1,362,827 shs

Market Capitalization

$3.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A